Special Issue

Molecular Mechanism of Amyloid Aggregation

Message from the Guest Editor

This Special Issue will primarily focus on the molecular mechanism of amyloid aggregation. A tremendous amount of research over the past couple of decades has generated a plethora of information. However, the molecular mechanism that generates aggregates at the initial phase of aggregation is still not understood in detail. Without the in-depth knowledge of these aggregates, which have been identified to be neurotoxic, it is challenging to develop any therapeutics to address the fatal neurodegenerative diseases. Emerging single molecular imaging and spectroscopic biophysical techniques are revealing a new structural and mechanistic understanding of amyloid aggregation that has not been seen previously. We cordially invite authors to submit original research for this Special Issue of Biomedicines.

Guest Editor

Dr. Siddhartha Banerjee

Department of Chemistry and Biochemistry, University of Alabama, Shelby Hall, Room 1009 Tuscaloosa, AL 35487, USA

Deadline for manuscript submissions

closed (31 August 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/185023

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).